摘要
塞利尼索(KPT-330)是由Karyopharm Therapeutics公司研发的人类核输出蛋白XPO-1抑制剂,英文通用名为selinexor。2019年7月3日由美国食品药品监督管理局(FDA)批准上市,用于治疗复发难治性多发性骨髓瘤(RRMM)。本文主要对塞利尼索的作用机制、临床前研究、药代动力学、临床研究及不良反应作一介绍。
Selinexor is a nuclear export protein XPO-1 inhibitor for the treatment of adult patients with relapsed or refractory multiple myeloma.It was developed by Karyopharm Therapeutics and approved by the U.S.Food and Drug Administration on July 3,2019.In this article,we mainly reviewed the mechanism of drug action,preclinical research,pharmacokinetics,clinical research and adverse reactions of selinexor.
作者
狄潘潘
贾淑云
DI Panpan;JIA Shuyun(Bozhou People’s Hospital,Bozhou,Anhui,236800,China)
出处
《肿瘤药学》
CAS
2019年第5期705-709,715,共6页
Anti-Tumor Pharmacy
